American biotechnology company 23andMe filed for Chapter 11 bankruptcy this month, after several quarters of falling revenue. The filing has put the data of millions of users’ data up for grabs, as bidders...
In this podcast, Motley Fool analyst Asit Sharma and host Mary Long discuss:
ME stock is surging after its bankruptcy filing, but should you buy the hype?
Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort....
Shares of 23andMe (NASDAQ: ME) imploded this week after the embattled genetic testing company filed for Chapter 11 bankruptcy and announced the immediate resignation of co-founder and CEO Anne Wojcicki....
23andMe has filed for Chapter 11 bankruptcy protection and its co-founder and CEO has resigned as the struggling genetic testing company continues its push to cut costs
23andMe stock crashed as the DNA kit company filed for Chapter 11 bankruptcy on Monday. Investors are recommended to stay away from all the drama.